Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1987 Aug;61(4):409-13.

A polymeric IgA response in serum can be produced by parenteral immunization

Affiliations

A polymeric IgA response in serum can be produced by parenteral immunization

F Mascart-Lemone et al. Immunology. 1987 Aug.

Abstract

The magnitude and the kinetics of the serum-specific polymeric (p-) and monomeric (m-) IgA antibody responses were analysed following parenteral stimulation with tetanus toxoid (TT) vaccine in 10 volunteers, 5-20 years after a previous boost. A rapid marked serum IgA antibody response involving both the monomeric and polymeric components of IgA was observed: m-IgA and p-IgA antibodies reached a peak of serum activity at about 11 days, around 6 days before the peak of IgG antibody activity. At the peak of the IgA response, p-IgA accounted for approximately half of the anti-TT activity (median 54%, 25-79%). However, p-IgA antibodies rapidly disappeared from serum over a few weeks, whereas the serum m-IgA antibody response was maintained over a prolonged period of time. For one subject out of five, anti-TT IgA were also detected in saliva with a peak of activity earlier than in serum. Calculation of the albumin relative coefficient of excretion for anti-TT IgA in this saliva suggested a local synthesis of these antibodies. The present study indicates that a polymeric IgA antibody response in serum can be produced by parenteral immunization in primed individuals, and it raises the question of the mechanisms that control polymeric versus monomeric IgA production.

PubMed Disclaimer

References

    1. Adv Exp Med Biol. 1974;45(0):433-5 - PubMed
    1. Adv Exp Med Biol. 1974;45(0):57-65 - PubMed
    1. Eur J Clin Invest. 1974 Aug;4(4):235-9 - PubMed
    1. J Immunol. 1982 Feb;128(2):990-5 - PubMed
    1. Lancet. 1982 Feb 27;1(8270):478-9 - PubMed

Publication types

LinkOut - more resources